A Combination of Low-Dose Systemic Etretinate and Topical Calcipotriol/Betamethasone Dipropionate Treatment for Hyperkeratosis and Itching in Olmsted Syndrome Associated with a TRPV3 Mutation

    October 2017 in “ Journal of dermatological science ”
    Takuya Takeichi, Katsuhiko Tsukamoto, Yusuke Okuno, Daisuke Kojima, Michihiro Kono, Yasushi Suga, Masashi Akiyama
    TLDR The combined treatment effectively managed severe skin issues in Olmsted syndrome.
    The document discussed a treatment approach for Olmsted syndrome (OS), a rare genetic skin disorder characterized by symmetrical keratoderma and hyperkeratotic plaques, often associated with TRPV3 mutations. The study explored the efficacy of combining low-dose systemic etretinate with topical calcipotriol/betamethasone dipropionate to manage hyperkeratosis and itching in OS patients. This combination therapy aimed to alleviate the severe skin manifestations and improve the quality of life for individuals suffering from this condition.
    Discuss this study in the Community →

    Cited in this study

    1 / 1 results